Market Cap 11.77B
Revenue (ttm) 705.14M
Net Income (ttm) -453.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -64.37%
Debt to Equity Ratio 0.00
Volume 1,807,370
Avg Vol 2,314,234
Day's Range N/A - N/A
Shares Out 161.97M
Stochastic %K 59%
Beta 0.33
Analysts Strong Sell
Price Target $82.95

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 931 9200
Address:
2855 Gazelle Court, Carlsbad, United States
TwongStocks
TwongStocks Nov. 14 at 12:02 PM
$IONS DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE) https://www.businesswire.com/news/home/20251113183682/en/DAWNZERA-donidalorsen-receives-positive-opinion-from-CHMP-recommended-for-approval-in-EU-for-hereditary-angioedema-HAE
0 · Reply
MargaretKemp553
MargaretKemp553 Nov. 14 at 4:32 AM
Having read $IONS sHTG olezarsen paper, truly believe $ARWR is coming out as winner in ApoC3 competition. While showing tremendous pancreatitis benefit, olezarsen INCREASED LDLc by over 50% (from low 60mg/dL levels); not seen in ARWR studies. This alone could be show-stopper to wide adoption; then there is liver fat increases (vuponersen hello), >50% have ALT/AST >ULN, increase in glycated hemoglobin (this is similar to ARWR).
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 14 at 4:07 AM
$IONS Current Stock Price: $69.83 Contracts to trade: $70 IONS Nov 21 2025 Call Entry: $1.35 Exit: $2.27 ROI: 68% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:53 AM
$IONS: The last close at $69.84 is below the 30-day moving average (MA30) of $71.9, indicating a bearish sentiment in the short term. The relative strength index (RSI) at 47.59 suggests the stock is neither overbought nor oversold, showing potential for movement in either direction. The 50-day moving average (MA50) at $68.4 is slightly below the current price, providing a support level. The 60-day high of $76.78 and low of $41.71 indicate a wide trading range, suggesting volatility. Directional bias leans bearish due to the price being below MA30, but the RSI indicates potential for a rebound. Suggested entry at $68.50, with a stop loss at $66.00 to limit downside risk. Target 1 at $72.00 (near MA30) and Target 2 at $75.00 (approaching the 60D high). Monitor for changes in RSI and price action for adjustments. https://privateprofiteers.com
0 · Reply
johnnygogogo
johnnygogogo Nov. 13 at 5:52 PM
$ARWR $IONS https://substack.com/home/post/p-178798206
1 · Reply
johnnygogogo
johnnygogogo Nov. 13 at 4:41 PM
$IONS all the new 0% convert owners are shorting the equity right now (“delta hedging”) because that’s how it works in this stupid fucking game.
2 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:59 AM
$IONS: The last close at $72.45 indicates a position above the 30-day moving average (MA30) of $71.63 and the 50-day moving average (MA50) of $67.95, suggesting a bullish trend. The RSI at 52.54 indicates neutral momentum, providing room for upward movement without being overbought. The 60-day high of $76.78 presents a potential resistance level, while the low of $41.71 establishes a significant support range. Trade Plan: - Directional Bias: Bullish, given the price above key MAs and neutral RSI. - Suggested Entry: $73.00 to capitalize on upward momentum. - Stop Loss: $70.00 to limit potential losses below recent support levels. - Target 1: $76.00, approaching the 60D high. - Target 2: $78.00, for extended gains beyond the high. Monitor market conditions closely, as volatility (ATR at 2.88) may impact price movements. https://privateprofiteers.com
0 · Reply
skeezbag
skeezbag Nov. 12 at 8:58 PM
$ARWROBVIOUSLY a pair trade going with $IONS and $ARWR You see the switch flip 5min before close
1 · Reply
Profitrip
Profitrip Nov. 12 at 8:56 AM
$CNTA prices $250M offering at $21.5 per ADS / today $ELDN launches proposed public offering of common stock and pre-funded warrants / yesterday $IONS announces proposed convertible offering to refinance 2026 convertible notes / yesterday $BHVN launches $150 million proposed public offering / yesterday $SLRX Salarius stock slides after pricing $7M offering / yesterday
0 · Reply
simonsp
simonsp Nov. 12 at 5:35 AM
$ARWR If you want realistic price for Arrowhead right now given assets- add ARWR MC + $IONS MC. You get the sHTG market which it will own, plus the pipeline. 11B plus 6B. 17B for the Best In Class Assets plus a mature pipeline with a myriad of P3s and burgeoning P2s. 130PPS.
1 · Reply
Latest News on IONS
Ionis to present at upcoming investor conferences

Nov 12, 2025, 4:00 PM EST - 1 day ago

Ionis to present at upcoming investor conferences


Ionis to hold third quarter 2025 financial results webcast

Oct 16, 2025, 7:05 AM EDT - 4 weeks ago

Ionis to hold third quarter 2025 financial results webcast


Ionis' brain disorder drug shows promise in clinical trial

Sep 22, 2025, 7:10 AM EDT - 7 weeks ago

Ionis' brain disorder drug shows promise in clinical trial


Ionis to host investors and analysts for Innovation Day 2025

Sep 8, 2025, 4:00 PM EDT - 2 months ago

Ionis to host investors and analysts for Innovation Day 2025


Is The 35% Rally In IONS Stock Just The Beginning?

Sep 3, 2025, 10:41 AM EDT - 2 months ago

Is The 35% Rally In IONS Stock Just The Beginning?


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN MRNA RGEN


US FDA approves Ionis' drug for rare genetic disorder

Aug 21, 2025, 11:58 AM EDT - 3 months ago

US FDA approves Ionis' drug for rare genetic disorder


Ionis to hold second quarter 2025 financial results webcast

Jul 16, 2025, 7:05 AM EDT - 4 months ago

Ionis to hold second quarter 2025 financial results webcast


TwongStocks
TwongStocks Nov. 14 at 12:02 PM
$IONS DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE) https://www.businesswire.com/news/home/20251113183682/en/DAWNZERA-donidalorsen-receives-positive-opinion-from-CHMP-recommended-for-approval-in-EU-for-hereditary-angioedema-HAE
0 · Reply
MargaretKemp553
MargaretKemp553 Nov. 14 at 4:32 AM
Having read $IONS sHTG olezarsen paper, truly believe $ARWR is coming out as winner in ApoC3 competition. While showing tremendous pancreatitis benefit, olezarsen INCREASED LDLc by over 50% (from low 60mg/dL levels); not seen in ARWR studies. This alone could be show-stopper to wide adoption; then there is liver fat increases (vuponersen hello), >50% have ALT/AST >ULN, increase in glycated hemoglobin (this is similar to ARWR).
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 14 at 4:07 AM
$IONS Current Stock Price: $69.83 Contracts to trade: $70 IONS Nov 21 2025 Call Entry: $1.35 Exit: $2.27 ROI: 68% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:53 AM
$IONS: The last close at $69.84 is below the 30-day moving average (MA30) of $71.9, indicating a bearish sentiment in the short term. The relative strength index (RSI) at 47.59 suggests the stock is neither overbought nor oversold, showing potential for movement in either direction. The 50-day moving average (MA50) at $68.4 is slightly below the current price, providing a support level. The 60-day high of $76.78 and low of $41.71 indicate a wide trading range, suggesting volatility. Directional bias leans bearish due to the price being below MA30, but the RSI indicates potential for a rebound. Suggested entry at $68.50, with a stop loss at $66.00 to limit downside risk. Target 1 at $72.00 (near MA30) and Target 2 at $75.00 (approaching the 60D high). Monitor for changes in RSI and price action for adjustments. https://privateprofiteers.com
0 · Reply
johnnygogogo
johnnygogogo Nov. 13 at 5:52 PM
$ARWR $IONS https://substack.com/home/post/p-178798206
1 · Reply
johnnygogogo
johnnygogogo Nov. 13 at 4:41 PM
$IONS all the new 0% convert owners are shorting the equity right now (“delta hedging”) because that’s how it works in this stupid fucking game.
2 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:59 AM
$IONS: The last close at $72.45 indicates a position above the 30-day moving average (MA30) of $71.63 and the 50-day moving average (MA50) of $67.95, suggesting a bullish trend. The RSI at 52.54 indicates neutral momentum, providing room for upward movement without being overbought. The 60-day high of $76.78 presents a potential resistance level, while the low of $41.71 establishes a significant support range. Trade Plan: - Directional Bias: Bullish, given the price above key MAs and neutral RSI. - Suggested Entry: $73.00 to capitalize on upward momentum. - Stop Loss: $70.00 to limit potential losses below recent support levels. - Target 1: $76.00, approaching the 60D high. - Target 2: $78.00, for extended gains beyond the high. Monitor market conditions closely, as volatility (ATR at 2.88) may impact price movements. https://privateprofiteers.com
0 · Reply
skeezbag
skeezbag Nov. 12 at 8:58 PM
$ARWROBVIOUSLY a pair trade going with $IONS and $ARWR You see the switch flip 5min before close
1 · Reply
Profitrip
Profitrip Nov. 12 at 8:56 AM
$CNTA prices $250M offering at $21.5 per ADS / today $ELDN launches proposed public offering of common stock and pre-funded warrants / yesterday $IONS announces proposed convertible offering to refinance 2026 convertible notes / yesterday $BHVN launches $150 million proposed public offering / yesterday $SLRX Salarius stock slides after pricing $7M offering / yesterday
0 · Reply
simonsp
simonsp Nov. 12 at 5:35 AM
$ARWR If you want realistic price for Arrowhead right now given assets- add ARWR MC + $IONS MC. You get the sHTG market which it will own, plus the pipeline. 11B plus 6B. 17B for the Best In Class Assets plus a mature pipeline with a myriad of P3s and burgeoning P2s. 130PPS.
1 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:35 AM
$IONS: The last close at $72.45 indicates a position above the 30-day moving average (MA30) of $71.63 and the 50-day moving average (MA50) of $67.95, suggesting a bullish trend. The RSI at 52.54 indicates neutral momentum, providing room for upward movement without being overbought. The 60-day high of $76.78 presents a potential resistance level, while the low of $41.71 establishes a significant support range. Trade Plan: - Directional Bias: Bullish, given the price above key MAs and neutral RSI. - Suggested Entry: $73.00 to capitalize on upward momentum. - Stop Loss: $70.00 to limit potential losses below recent support levels. - Target 1: $76.00, approaching the 60D high. - Target 2: $78.00, for extended gains beyond the high. Monitor market conditions closely, as volatility (ATR at 2.88) may impact price movements. https://privateprofiteers.com
0 · Reply
johnnygogogo
johnnygogogo Nov. 12 at 12:54 AM
$IONS ok, real talk, no troll. Why is Ionis refinancing 0% converts 7 months before expiration (I think June 2026 expiry, but need to double check) and exactly one week before scheduled $ARWR REDEMPLO PDUFA / potential launch? Doesn’t that, coupled with plenty of insider sales at Ionis (see the Form 4’s) inherently signal weakness / low optimism on Tryngolza FCS and SHTG mkt share? Or is it “refi when you can, not when you have to?” Guess we’ll have to wait on pricing and not sure yet who’s buying the new bonds (though I have a fairly good idea who will be selling the bonds on behalf of the company). @skeezbag @GMH21 @LeftyT @BikeRieder @Pantherfan7979 @simonsp
5 · Reply
Mrstock2255
Mrstock2255 Nov. 11 at 11:50 PM
0 · Reply
johnnygogogo
johnnygogogo Nov. 10 at 8:45 PM
$IONS Hey Grok, is Art a sad little lonely man? @skeezbag
2 · Reply
IN0V8
IN0V8 Nov. 10 at 5:34 PM
$IONS Buying Opportunity Leerink Partners raises target price to $83 from $72
1 · Reply
tterhaar
tterhaar Nov. 10 at 3:13 PM
$IONS what’s this all about? 🤦🏼‍♂️
1 · Reply
Drashkawisha
Drashkawisha Nov. 10 at 2:07 PM
$ARWR It's crunch time. 18 days to the PDUFA. Yes, $IONS is close behind, but being first to market matters. Betting on the RNAi platform to deliver a clean label. In a duopoly, the best-in-class wins, but the first-in-class gets the head start.
2 · Reply
OpenOutcrier
OpenOutcrier Nov. 10 at 1:40 PM
$IONS (-2.8% pre) Ionis Pharmaceuticals Reports Positive Phase 3 Study Results https://ooc.bz/l/83860
0 · Reply
Bullish_Trader555
Bullish_Trader555 Nov. 10 at 12:40 PM
$IONS Ionis Pharmaceuticals Study Results Of Olezarsen For Severe Hypertriglyceridemia Show Up To 72% Placebo-adjusted Mean Reduction In Fasting Triglyceride Levels At Six Months, With Reductions Sustained Through 12 Months $LLY
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 12:27 PM
HC Wainwright & Co. has adjusted their stance on Ionis Pharmaceuticals ( $IONS ), setting the rating to Buy with a target price of 100 → 110.
0 · Reply
masonat
masonat Nov. 8 at 6:34 PM
$IONS 85% reduction in pancreatitis!
0 · Reply
DrGreenThumb
DrGreenThumb Nov. 8 at 5:22 PM
$IONS https://stocks.apple.com/Ae6ooL9SgRV-Cz5Lsa73CCg
0 · Reply